Managing asthma in primary care: Putting new guideline recommendations into context

Mayo Clinic Proceedings

Volumn 84, Issue 8, 2009, Pages 707-717

  Wechsler, Michael E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FORMOTEROL; LEUKOTRIENE; MONTELUKAST; OMALIZUMAB; SALMETEROL; THEOPHYLLINE; ZILEUTON;

ASTHMA; CLINICAL FEATURE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; TREATMENT PLANNING;

EID: 68149161078     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.8.707     Document Type: Review

References (29)

1. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J. 2008;31(2):320-325. Epub 2007 Oct 24.
2. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114(1):40-47.
3. Stempel DA, McLaughin TP, Stanford RH, Fuhlbrigge AL. Patterns of asthma control: a 3-year analysis of patient claims. J Allergy Clin Immunol. 2005;115(5):935-939.
4. Sapra SJ, Broder MS and Chang E. Alignment with the revised NHLBI 2007 asthma guidelines, Expert Panel Report 3 (EPR 3) in a large payer database. J Allergy Clin Immunol. 2009;123(2)(suppl 1):S117.
5. Holgate ST, Price D, Valovirta E. Asthma out of control? A structured review of recent patient surveys. BMC Pulm Med. 2006;6(suppl 1):S2.
6. Horne R, Price D, Cleland J, et al. Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med. 2007;7:8.
7. Barnes PJ. The size of the problem of managing asthma. Respir Med. 2004;98(suppl 2):S4-S8.
8. Ohar JA. Asthma treatment guidelines: current recommendations, future goals. P&T Digest. 2005;2(6):23-27.
9. US Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 07-40511-440. Bethesda, MD: US Dept of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln. pdf. Accessed May 20, 2009.
10. Long AA. Addressing unmet needs in asthma care. P&T Digest. 2005;2(6):16-22.
11. Schatz M. Pharmacotherapy of asthma: what do the 2007 NAEPP guidelines say? Allergy Asthma Proc. 2007;28(6):628-633.
12. Kelly HW. Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines. J Allergy Clin Immunol. 2007;120(5):989-994.
13. Berlow BA. Eight key questions to ask when your patient with asthma doesn't get better. Am Fam Physician. 1997;55(1):183-189, 192-194.
14. Lilly CM, Churg A, Lazarovich M, et al. Asthma therapies and Churg-Strauss syndrome. J Allergy Clin Immunol. 2002;109(1):S1-S19.
15. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med. 2002;166(8):1044-1049.
16. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 2001;163(7):1693-1722.
17. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998;12(5):1209-1218.
18. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902-907.
19. Vollmer WM, Markson LE, O'Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med. 1999;160(5, pt 1):1647-1652.
20. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59-65.
21. Hanania NA. Targeting airway inflammation in asthma: current and future therapies. Chest. 2008;133(4):989-998.
22. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician's perception. Chest. 2006;130(1)(suppl):41S-53S.
23. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004;59(1):16-20.
24. Mjaanes CM, Whelan GJ, Szefler SJ. Corticosteroid therapy in asthma: predictors of responsiveness. Clin Chest Med. 2006;27(1):119-132, vii.
25. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373-1377. Epub 2007 Nov 9.
26. Prenner BM. Asthma 2008: targeting immunoglobulin E to achieve disease control. J Asthma. 2008;45(6):429-436.
27. Kuhn R. Immunoglobulin E blockade in the treatment of asthma. Pharmacotherapy. 2007;27(10):1412-1424.
28. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788-797. Epub 2009 Mar 17. DOI10.1111/j.1365-2222.2009.03214.x.
29. Broder M, Chang E, Ory C, Kamath T, Sapra S. Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care population. [published online ahead of print January 16, 2009]. Allergy Asthma Proc. 2009 Mar-Apr; 30(2):148-157. Epub2009 Jan 16. DOI. 10.2500/aap.2009.30.3190